Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Statesville, NC
NPI: 1437441052Primary Practice Location
Piedmont Healthcare, PA
208 Old Mocksville Rd, Statesville, NC
Primary Employer
Piedmont Healthcare, P.A.
piedmonthealthcare.com
HQ Phone
Get M.D. Matthew's Phone Numberphone_androidMobile
Get M.D. Matthew's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
NC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 85 | 124 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 67 | 111 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 54 | 79 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 47 | 47 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 15 | 29 |
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Authors: Ann Bass, Regina Berkovich, Brian Steingo, Gabriel Pardo, Carolina Ionete
Publication Date: 2020-06-24
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Authors: Ontaneda, Daniel, Nicholas, Jacqueline, Carraro, Matthew, Zhou, Jia, Hou, Qiang, Babb, Jaanai, Riester, Katherine, Mendoza, Jason P, Livingston, Terrie, Jhaveri, Mehul
Journal: Mult Scler Relat Disord
Publication Date: 2018-10-10
Lead Sponsor: Johns Hopkins University
Collaborators: Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Intervention / Treatment: OTHER: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, OTHER: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: Interferon beta-1a, BIOLOGICAL: Alemtuzumab 12 mg, BIOLOGICAL: Alemtuzumab 24 mg
Lead Sponsor: Genzyme, a Sanofi Company
Intervention / Treatment: DRUG: alemtuzumab GZ402673
